Full Text
PBI19 Cost-Effectiveness Analysis of Adalimumab Biosimilar for Rheumatoid Arthritis in Brazil Compared to Delayed Biologic Treatment Initiation

Abstract

Authors

S. Tanaka J.K. Porter F. Santos G. Aratangy

Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×